U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530887) titled 'NO Re-excision MelanomA - NORMA 2' on March 26.

Brief Summary: This multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes. A total of 1,749 patients with pT1b-pT4b cutaneous melanoma without evidence of metastases will be randomized to either standard re-excision according to current guidelines or no re-excision. Sentinel lymph node biopsy and adjuvant systemic therapy will be performed as indicated in both groups.

The primary objective is to compare relapse-free survival (RFS) between the two groups. Secondary object...